1 / 36

The Heart in Hypertension

The Heart in Hypertension. Jamil Mayet. Left Ventricular Hypertrophy - a historical perspective. Association between renal disease and LVH Richard Bright 1836 Hypertrophy of large and small vessels related to LVH in kidney disease George Johnson 1852

hope-munoz
Download Presentation

The Heart in Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Heart in Hypertension Jamil Mayet

  2. Left Ventricular Hypertrophy- a historical perspective • Association between renal disease and LVH • Richard Bright 1836 • Hypertrophy of large and small vessels related to LVH in kidney disease • George Johnson 1852 • Vascular changes and LVH without renal disease • Gull and Sutton 1872 • BP measured in life correlated with post-mortem heart weight • Evans 1921

  3. Definition of LVH • Healthy cohort of subjects • No high BP, diabetes, CV disease, obesity • LVH defined as LVMI > mean + 2SD • Framingham Study LVMI > 131g/m2 males; > 100g/m2 females • Cornell, New York LVMI > 134g/m2 males; > 110g/m2 females Levy et al. Am J Cardiol 1987;59:956-60. Devereux et al. JACC 1984;4:1222-30.

  4. Risk factors for LVH • Blood pressure • Age • Gender • Race • Genetic factors • Obesity • Physical activity

  5. Pathophysiology of LVH • High BP   LV wall stress • Wall stress  1/ wall thickness • LV wall thickening   wall stress • Myocyte hypertrophy and  collagen matrix • Mediators: • Mechanical: preload & afterload • Neurohormonal: angiotensin II, sympathetic NS

  6. Clinic versus mean 24 hour systolic BP and LVMI Mayet al et. J Cardiovasc Risk 1995;2:255-61.

  7. Methods of detecting LVH • Clinical examination • Chest radiography • Electrocardiography • Echocardiography • (CT, MRI)

  8. Sensitivity and specificity of ECG criteria for LVH Devereux et al 1983, Murphy et al 1985, Levy et al 1990, Lee et al 1992, Devereux et al 1993, Schillaci et al 1994, Crow et al 1995, Norman et al 1995, Chapman et al (in press)

  9. Cardiothoracic ratio and CHD mortality:Whitehall study *Adjusted for age, BP, HR, cholesterol, smoking, angina and ECG ischaemia Hemingway et al. BMJ 1998; 316: 1353-4.

  10. Cardiovascular risk in subjects with ECG-LVH: Framingham Age-adjusted risk-ratio *P<0.0001 Kannel. Eur Heart J 1992; 13 (suppl D): 82-88

  11. Risks of X-ray and ECG LVH:Framingham Age-adjusted biennial rate per 1000 Data include men and women, aged 35-94 Kannel. Eur Heart J 1992; 13 (suppl D): 82-88

  12. Penn convention for M-mode measurements • Peak of QRS • Endocardium excluded from SWT and PWT • Endocardium included in LVID LV mass = 1.04[(SWT+LVID+PWT)3 - (LVID)3 - 14g Divide by body surface area to get LV mass index Septum (SWT) LV cavity (LVID) Posterior wall (PWT) Devereux & Reichek Circulation 1977;55:613-8

  13. ASE guidelines for M-mode measurements • Start of QRS • Endocardium included in SWT and PWT • Endocardium excluded from LVID LVM = 0.8{1.04[ (SWT+LVID+PWT)3 - (LVID)3]} + 0.6 g Divide by body surface area to get LV mass index Septum (SWT) LV cavity (LVID) Posterior wall (PWT) Devereux et al. Am J Cardiol 1986;57:450-8

  14. Area-length method for calculation of LV mass LVmass=1.05[5/6(A1xL1)-5/6(A2xL2)] Divide by body surface area to get LV mass index Reichek et al. Circulation 1983;67:348-52

  15. 4-year age-adjusted incidence of cardiovascular disease according to LVMI Age-adjusted incidence/ 100 subjects LVMI (g/m2) Redrawn from Levy et al; NEJM 1990; 322: 1561-6.

  16. 4-year age-adjusted cardiovascular mortality Incidence of cardiovascular mortality according to presence or absence of LVH P=ns P<0.001 Redrawn from Levy et al, NEJM 1990; 322: 1561-6.

  17. Risks associated with LVM and geometry Cardiovascular events† Total mortality* % patients RWT LVMI (g/m2) LVMI (g/m2) *P<0.001, †P=0.03 Koren et al. Ann Int Med 1991; 114: 345-352.

  18. Regression of LVH by drug treatment:meta-analysis of RCTs Mean %  in LVMI Between treatment P<0.01 Schmieder et al. JAMA 1996; 275: 1507-1513

  19. Prognostic significance of Echo LVM regression † Events/ 100 patient years * *P=0.04, †P=0.0004 after adjustment for age. Verdecchia et al. Circulation 1998; 97: 48-54

  20. Prognostic significance of ECG voltage changes: Framingham * OR for CV events (2 years) * *P<0.05 Levy et al. Circulation 1994; 90: 1786-1793

  21. Age-adjusted risk of congestive heart failure by hypertensive status <140/90 >160/90 Kannel WB. Framingham

  22. The progression from hypertension to congestive heart failure • 5143 subjects in Framingham study • 392 new cases of clinical CCF after mean follow up of 20 years • In 91% hypertension antedated CCF • MI present in 52% of hypertensive men and 34% of hypertensive women with CCF • Median survival after CCF diagnosis in ht 1.37 years in men and 2.48 in women Levy et al. JAMA 1996;275:1557-62

  23. Age-adjusted BP parameters and CHF risk Hazard Ratio 120-139 140-159 70-79 80-89 54-67 <120 >159 <70 >89 <54 >67 Chae et al. JAMA199;281:634-9

  24. Arterial stiffening in hypertension • Increased PW velocity with early wave reflection • Increased central systolic pressure and lower diastolic pressure • Discrepancy between central and peripheral pressures lessened • Therefore peripheral BP underestimates central effects

  25. Reducing arterial stiffness as a therapeutic goal • Later wave reflection reduces peak central pressure which is caused by summation of systolic wave and reflected wave • In periphery peak pressure is not a summation wave and so there is less of a decrease • Reducing stiffness causes preferential decrease in central compared with peripheral pressures

  26. Non-pharmacological approaches to reducing arterial stiffness • Increased arterial stiffness in obese subjects with improvement following weight reduction • Moderate aerobic exercise increases arterial compliance • Subjects with high salt intake have better arterial distensibility than those with low intake. • Improvement following salt restriction

  27. Stiffness LV Outcome impact regression data ?+ + No a -blockers +++ +++ No ACE-inhibitors + + Yes b -blockers ++ ?? No b -blockers ‘extra’ +++ ++ Yes ++ Ca antagonists + +/++ Yes + thiazides Relation between vascular and LV impacts of antihypertensives

  28. Diastolic heart failure • Symptoms/signs of heart failure with normal or mildly impaired LV systolic function • Prevalence depends on clinical definition of heart failure • May be up to 30% of cases with heart failure • Diastolic dysfunction in hypertensives is very common, particularly in those with LVH

  29. Pathophysiology of diastolic dysfunction • Impaired relaxation • Energy dependent and sensitive to ischaemia • Coronary artery disease • Microvascular ischaemia (arteriolar rarefaction, arteriole wall thickening, perivascular fibrosis, endothelial dysfunction, relative myocyte hypertrophy) • Decreased compliance • Increase in myocardial collagen

  30. Echocardiographic assessment • 2D echo to assess systolic function • Doppler echo • Transmitral flow • E/A wave ratio • E wave deceleration time • IVRT

  31. Doppler patterns of diastolic dysfunction • Impaired relaxation • Reduced E/A ratio • Increased EDT • Increased IVRT • Restriction • LA pressure increases due to myocardial stiffness • High peak E wave velocity • Short EDT • Very short IVRT

  32. Treatment of diastolic heart failure • Treat underlying cause eg ischaemia • Impaired relaxation • Theoretically rate-limiting agents effective • Beta-blockers, verapamil • Reduce HR and prolong diastole • Reduce myocardial oxygen demand • Lower BP and reduce LVH

  33. Treatment of diastolic heart failure • Restriction • Drugs which reduce fibrosis and lower LA pressure theoretically should be effective • ACEI • AII blockers • Diuretics • If LA pressure lowered too much cardiac output significantly worsened • Can cause significant morbidity

More Related